<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429402</url>
  </required_header>
  <id_info>
    <org_study_id>98-2237C</org_study_id>
    <nct_id>NCT01429402</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin to Improve Results in Cleft Lip Repair</brief_title>
  <official_title>Botulinum Toxin to Improve Results in Cleft Lip Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif) is widely used for facial&#xD;
      rejuvenation and many other medical indications. It induces chemodenervation through its&#xD;
      action on the presynaptic neuron, preventing release of acetylcholine, which leads to&#xD;
      functional denervation of striated muscle for 2 to 6 months after injection. The use of&#xD;
      botulinum toxin injection to reduce the facial scar is logical because this could reduce the&#xD;
      tensile distracting force of the upper lip caused by the orbicularis oris muscle pull.&#xD;
      Tollefson has demonstrate that botulinum toxin injection has decrease lip tension after&#xD;
      primary lip repair in 3 children at 3-6 months of age The main aim of this randomized trial&#xD;
      is to compare whether post-operative peri-surgical-injection of botulinum toxin into&#xD;
      bilateral orbicularis oris muscles can improve scar formation for both primary and secondary&#xD;
      cleft lip surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial primarily designed to compare the scarring after&#xD;
      primary and secondary cleft lip repair using post-operative botulinum toxin injection. There&#xD;
      will be 4 main groups in this study:-&#xD;
&#xD;
        1. Study group I: For primary lip surgery, immediately after primary lip repair will&#xD;
           received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant&#xD;
           oriented orbicularis ocuris muscle via 4 superficial injection site (Tollefson TT 2006).&#xD;
&#xD;
        2. Study group II: For revision lip surgery, immediately after revision lip surgery 3&#xD;
           injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and&#xD;
           operative wound are injected over both sides of upper lip in a adult on the operation&#xD;
           room.&#xD;
&#xD;
        3. Control group I : Similar amount (in C.C.) of normal saline will be injected after&#xD;
           primary lip surgery at 3 months of age.&#xD;
&#xD;
        4. Control group II: Similar amount (in C.C.) of normal saline will be injected after&#xD;
           revision lip surgery (secondary cleft lip repair).&#xD;
&#xD;
           4. ELIGIBILITY 4.1 Inclusion criteria for the primary lip repair group (i) Baby born&#xD;
           with cleft lip who will receive primary lip repair at 3 months of age (iii) Written&#xD;
           informed consent given by parent/guardian.&#xD;
&#xD;
      4.2 Inclusion criteria for the secondary lip repair group (i) Adult &gt; 16 years old. (ii)&#xD;
      Moderate to severe secondary cleft lip and/or nose deformity that warrants corrective&#xD;
      surgery.&#xD;
&#xD;
      (iii) Written informed consent given by parent/guardian/patient.&#xD;
&#xD;
      4.3 Patient numbers: 60 for primary lip repair and 60 for secondary lip repair&#xD;
&#xD;
      4.31 Sample size calculation: 10 consecutive patient selected from our OPD on march 2009.&#xD;
      Vancouver Scar Scale means 4.6 with SD 1.264911 (rage 3-7). If the study group with&#xD;
      improvement of 1 is clinical significant, giving power 0.8 with the same SD, the sample size&#xD;
      calculated will be 26.&#xD;
&#xD;
      Using Terason Ultrasound (capacity of measured 1/100 cm or 1/10 mm) the scar width mean is&#xD;
      1.13 mm with SD .6201254. If the study group with improvement of 0.5 mm as clinical&#xD;
      significant, giving the power of 0.8 with the same SD, the sample size calculated will be 25.&#xD;
&#xD;
      We will use 30 patients for each group.&#xD;
&#xD;
      4.41 Exclusion criteria for primary lip repair&#xD;
&#xD;
        1. Combined other craniofacial anomalies&#xD;
&#xD;
        2. Without permission of parent/guardian, without signed informed consent by&#xD;
           parent/guardian.&#xD;
&#xD;
      4.42 Exclusion criteria for the secondary lip repair&#xD;
&#xD;
        1. Less than 15 years old&#xD;
&#xD;
        2. Mild secondary cleft lip and / or nose deformity that does not warrant corrective&#xD;
           surgery.&#xD;
&#xD;
        3. Without written informed consent.&#xD;
&#xD;
        4. Without permission of parent/guardian, the patient signed the consent himself.&#xD;
&#xD;
           5. Botulinum Toxin injection 5.1 For Study group I: Injections are placed into the&#xD;
           orbicularis oris muscle 5 mm adjacent to the scar and the vermilion border on each side&#xD;
           of the operative wound (A total of 3 injections per side making a total of 6 injections&#xD;
           per patient). 1-2U/kg (total dosage for baby) and 2.5 U (adult ) of botulinum toxin&#xD;
           (Botox; allergen, Inc., Irvine, Calif) will be used for each injection. A total dosage&#xD;
           of 15 U (for adult) will be injected into each patient.&#xD;
&#xD;
           For control group a similar amount of Normal saline will be injected.&#xD;
&#xD;
           6. STUDY VISITS AND ASSESSMENTS 6.1 Registration and Randomization (i) Confirmation of&#xD;
           eligibility (ii) Information Sheet (iii) Written informed consent (iv) Registration of&#xD;
           baby and adult into study and randomization (v) Scheduling of patient for botox&#xD;
           injection immediately after surgery.&#xD;
&#xD;
           6.2 Follow-up Assessments 6.2.1 Vancouver scar scale (Sullivan T 1990) measures&#xD;
           pigmentation, vascularity, pliability and scar height on the postoperative 6 month F/U.&#xD;
&#xD;
           Ultrasonography measurement of the scar (Fong SS 1997)&#xD;
&#xD;
           For both primary and secondary lip surgery, the patient will receive postoperative&#xD;
           follow up during 1wk, 1mo, 3mo, 6mo. On the 1st week postoperative follow up, the&#xD;
           stitches will be removed, 3M taping will be placed over the wound to reduce surface&#xD;
           tension and minimize the scar formation. On the 6th mo follow up, a lay person will&#xD;
           assess the scar using the Vancouver scar and a plastic surgeon will use ultrasonography&#xD;
           to measure the scar.&#xD;
&#xD;
           The Independent T-Student test will be used to analyze the statistical significance&#xD;
           between the two groups.&#xD;
&#xD;
           Photographic measurement of scar The scar width of the patient's picture at 6 month&#xD;
           after surgery will be measured using photoshop CS3 extended. One ruler will be placed on&#xD;
           the patient's lip before taken the photo. Then the scar width could be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2000</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vancouver Scar scale</measure>
    <time_frame>6 month</time_frame>
    <description>Vancouver scar scale measures pigmentation, vascularity, pliability and scar height on the postoperative 6 month F/U.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrasonography scar measurement</measure>
    <time_frame>6 month</time_frame>
    <description>On the 6th mo follow up, ultrasonography to measure the scar width will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photographic measurement</measure>
    <time_frame>6 month</time_frame>
    <description>The scar width of the patient's picture at 6 month after surgery will be measured using photoshop CS3 extended. One ruler will be placed on the patient's lip before taken the photo. Then the scar width could be measured.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Scar</condition>
  <arm_group>
    <arm_group_label>study group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed</description>
    <arm_group_label>study group I</arm_group_label>
    <other_name>Botox ( Allergan, Inc., Irvine, Calif)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Type A</intervention_name>
    <description>b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)</description>
    <arm_group_label>Study Group II</arm_group_label>
    <other_name>Botox ( Allergan, Inc., Irvine, Calif)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.</description>
    <arm_group_label>Control Group I</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).</description>
    <arm_group_label>Control II</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for the primary lip repair group&#xD;
&#xD;
          -  Baby born with cleft lip who will receive primary lip repair at 3 months of age&#xD;
&#xD;
          -  Written informed consent given by parent/guardian.&#xD;
&#xD;
        Inclusion criteria for the secondary lip repair group&#xD;
&#xD;
          -  Adult &gt; 16 years old.&#xD;
&#xD;
          -  Moderate to severe secondary cleft lip and/or nose deformity that warrants corrective&#xD;
             surgery.&#xD;
&#xD;
          -  Written informed consent given by parent/guardian/patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those patient not fit inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun-Shin Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip Kuo-Ting Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chun Shin Chang</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Shin Chang, M.D.</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>2340</phone_ext>
      <email>frankchang@adm.cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chun-Shin Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Kuo Ting Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Tollefson TT, Senders CM, Sykes JM, Byorth PJ. Botulinum toxin to improve results in cleft lip repair. Arch Facial Plast Surg. 2006 May-Jun;8(3):221-2.</citation>
    <PMID>16702537</PMID>
  </reference>
  <reference>
    <citation>Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, Sherris DA. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006 Aug;81(8):1023-8.</citation>
    <PMID>16901024</PMID>
  </reference>
  <reference>
    <citation>Gassner HG, Sherris DA, Friedman O. Botulinum toxin-induced immobilization of lower facial wounds. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):140-2. doi: 10.1001/archfacial.2009.3.</citation>
    <PMID>19289689</PMID>
  </reference>
  <reference>
    <citation>Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000 May;105(6):1948-53; discussion 1954-5.</citation>
    <PMID>10839391</PMID>
  </reference>
  <reference>
    <citation>Larrabee WF Jr. Treatment of Facial Wounds with Botulinum Toxin A Improves Cosmetic Outcome in Primates. Plast Reconstr Surg. 2000 May;105(6):1954-1955.</citation>
    <PMID>11242330</PMID>
  </reference>
  <reference>
    <citation>Lee BJ, Jeong JH, Wang SG, Lee JC, Goh EK, Kim HW. Effect of botulinum toxin type a on a rat surgical wound model. Clin Exp Otorhinolaryngol. 2009 Mar;2(1):20-7. doi: 10.3342/ceo.2009.2.1.20. Epub 2009 Mar 26.</citation>
    <PMID>19434287</PMID>
  </reference>
  <reference>
    <citation>Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2002 Feb;18(1):35-9.</citation>
    <PMID>11823931</PMID>
  </reference>
  <reference>
    <citation>Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg. 2006 May;117(6):1758-66; discussion 1767-8.</citation>
    <PMID>16651948</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>September 4, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Botulinum toxin A.</keyword>
  <keyword>Cleft lip scar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cleft Lip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

